Dianthus Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Dianthus Therapeutics

03/08/2026 23:12

Dianthus Therapeutics Inc DNTH.OQ DNTH.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 (estimated) for the period ending June 30 2026
The New York City-based  company is expected to report a 34.0% increase in revenue to $258.58 thousand from $193 thousand a year ago, according to the mean estimate from 12 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Dianthus Therapeutics Inc is for a loss of 86 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Dianthus Therapeutics Inc is $125.00, about 17.9% above its last closing price of $106.02
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.06
-1.07
-0.85
Beat
20.7
Dec. 31 2026
-0.88
-1.08
-1.43
Missed
-32.9
Sep. 30 2025
-0.79
-0.86
-0.97
Missed
-12.5​
Jun. 30 2025
-0.86
-0.87
-0.88
Missed
-1
​​Mar. 31 2025
-0.83
-0.85
-0.82
Beat
3.4
Dec. 31 2024
-0.88
-0.85
-0.81
Beat
4.8​
Sep. 30 2024
-0.58
-0.59
-0.74
Missed
-24.5
Jun. 30 2024
-0.57
-0.55
-0.51
Beat
6.5
This summary was machine generated August 3 at 22:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)